Clinical Meningococcal Polysaccharide Vaccine

The vaccine is indicated for active immunization against invasive meningococcal disease caused by epidemic Neisseria meningitidis serogroups A,C,Y,W135. [Description]The vaccine is a preparation of preparation polysaccharide antigens extracted from the culture of Neisseria meningitidis group ACYW135 respectively and Iyophilized after addition of an appropriate stabilizer. The final product looks like a white crisp cake. It shall dissolve in the accompanying Phosphate buffered saline (PBS) immediately, and turn into a clear liquid after reconstitution.Active constituent: Neisseria meningitidis group ACYW135 capsular polysaccharides.Subsidiary materials: All the components of subsidiary materials approved shall be listed.Vaccine diluent: Sterile, pyrogen-free PBS.[Specifications]0.5 ml of reconstituted vaccine per container. 0.5 ml per single human dose, containing  200μg of meningococcal polysaccharide (50μg of each polysaccharide of group A,C,Y,W135). [Administration and dosage](1) Reconstitute the vaccine with the accompanying PBS as the stated value. Shake and inject immediately.(2) The vaccine shall be injected s.c. at deltoid insertion area of the lateral upper arm.(3) One single human dose of 0.5 ml vaccine is required. The immunization shall be carried out before the epidemic season of epidemic cerebrospinal meningitis.[Adverse reactions]Common adverse reactions:(1) Pain, tenderness, mild or moderate erythema, swelling and infiltration at the injection site with